DSM to sell its resins, materials businesses to focus on nutrition and health

By Jane Byrne contact

- Last updated on GMT

© GettyImages/ipopba
© GettyImages/ipopba

Related tags: Romer labs, Mycotoxins, Gut health

DSM has agreed to sell its resins and functional materials (RFM) and associated businesses to Covestro for an equity value of €1.6bn, as it continues to focus on divisions core to its nutrition and health linked operational goals.

The proposed divestment follows DSM’s recent acquisitions of the Biomin and Romer Lab’s business from the Erber Group, which is set to close shortly, along with Danish human milk oligosaccharides supplier, Glycom, and specialty dairy solutions provider, CSK.

Completion of the deal with Covestro, which is subject to the customary conditions and approvals, is expected to occur in the first half of 2021.

DSM said it expects to receive approximately €1.4bn net in cash following closing, including repayment of RFM’s net debt, and after transaction costs and capital gains tax.

Geraldine Matchett and Dimitri de Vreeze, Co-CEOs of Royal DSM, commented: “This sale builds on our approach of actively managing our businesses, as DSM continues to evolve as a purpose-led, science-based company operating in the fields of nutrition, health and sustainable living. The deal delivers strong value to DSM and is strategically attractive for all parties.”  

When DSM acquired the Erber Group businesses in June this year, it entered the mycotoxin control business “as the world leader.” ​The move was also set to enhance the company’s position in the animal gut performance management market.

In an evaluation​ of that deal, commentators said the acquisition should help DSM benefit from a transition to more 'sustainable' farming globally.

"Still, Erber needs to increase its current €330m in revenue by over a tenth annually over the next five years for DSM to make a return broadly in line with an estimated 10% cost of capital, assuming a 20% operating margin and an 18% tax rate."

The use of proceeds from the sale of the RFM businesses has not yet been determined.

"Assuming all transactions proceed as expected, we will be broadly at the same leverage levels as we were prior to the Glycom and Erber transactions. Therefore, as of now, the intention is to continue to allocate that capital according to our existing priorities as we always do. One of those priorities, which were set back in 2018, is for value creation acquisitions, predominately in nutrition. But that is not our only capital allocation approach and we will need to see once the transactions conclude,"​ a spokesperson for DSM told FeedNavigator. 

Related news

Show more

Related products

show more

Effect of yeast nutritional factors on immune health

Effect of yeast nutritional factors on immune health

Angel Yeast Co., Ltd. | 07-Sep-2020 | Technical / White Paper

The nutritional status of animals affects their immune functions and resistance to diseases. Hence, nutrition deficiency can cause damage to the animal’s...

Multi-mycotoxin contamination, an underestimated risk

Multi-mycotoxin contamination, an underestimated risk

Wisium (part of ADM) | 01-Sep-2020 | Technical / White Paper

One single fungus can produce different mycotoxins which can lead to several cases of co-contaminations. Various mycotoxins produced by different fungus...

Effect of YeaVita R on rumen internal environment

Effect of YeaVita R on rumen internal environment

Angel Yeast Co., Ltd. | 06-Jul-2020 | Technical / White Paper

YeaVita R is a safe and efficient Saccharomyces cerevisiae strain from rumen, which does not contain any carrier and has more than 20 billion viable strains...

Related suppliers

Follow us

Products

View more

Webinars